Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2023-05-30 20:55:57 UTC |
---|
HMDB ID | HMDB0000682 |
---|
Secondary Accession Numbers | - HMDB0003309
- HMDB00682
- HMDB03309
|
---|
Metabolite Identification |
---|
Common Name | Indoxyl sulfate |
---|
Description | Indoxyl sulfate, also known as 3-indoxyl sulfate, is a member of the class of organic compounds known as arylsulfates. These are organic compounds containing a sulfate group that carries an aryl group through an ether group. Indoxyl sulfate is a metabolite of the common amino acid tryptophan and is derived through the consumption, digestion and microbial processing of protein-rich foods. Indoxyl sulfate is technically a bacterial co-metabolite, meaning that it is derived from both bacterial and host metabolism. Specifically, it is generated from dietary L-tryptophan which is converted to indole in the large intestine via tryptophanase-expressing gastrointestinal bacteria (PMID: 27102537 ). The resulting indole is converted to indoxyl in the liver via enzyme-mediated hydroxylation by the CYP450 enzyme CYP2E1 (PMID 11808865 ). Subsequently, indoxyl is converted into indoxyl sulfate by the SULT1A1 sulfotransferase enzyme in the liver (PMID: 12064372 ). Indoxyl sulfate has been identified as a uremic toxin according to the European Uremic Toxin Working Group (PMID: 22626821 ) and is classified as a protein-bound uremic solute. Indoxyl sulfate is known to bind to serum albumin (PMID: 22626821 ), to be transported by the OAT1 transporter (PMID: 34678967 ) and to be an agonist for the arylhydrocarbon receptor (AhR) (PMID: 32527975 ). High concentrations of indoxyl sulfate in whole blood or blood plasma are known to be associated with the development and progression of chronic kidney disease (CKD) as well as the development of cardiovascular disease (CVD) in humans and other mammals (PMID: 28754616 ). As a uremic toxin, indoxyl sulfate is known to stimulate glomerular sclerosis (PMID: 8035108 ), interstitial fibrosis (PMID: 33138205 ) and increase the rate of progression of renal failure. Indoxyl sulfate is a known tubular toxin (i.e., a renal tubule toxin) and directly induces apoptotic and necrotic cell death of tubular cells in the kidney (PMID: 33138205 ). Indoxyl sulfate upregulates signal transducers and activators of transcription 3 phosphorylation leading to increases in TGF-β1, monocyte chemotactic protein-1 and alpha-smooth muscle actin production, all of which participate in interstitial inflammation, renal fibrosis and, consequently, CKD progression (PMID: 33138205 ). Indoxyl sulfate is also a known cardiotoxin (PMID: 30200452 ). In plasma, indoxyl sulfate induces endothelial dysfunction by inhibiting endothelial proliferation and migration as well as disrupting wound repair in vitro (PMID: 14717914 ). Indoxyl sulfate is known to impair angiogenesis by suppressing endothelial cell tube formation and endothelial cell proliferation via chronic aryl hydrocarbon receptor (AhR) activation. Many studies suggest that indoxyl sulfate increases oxidative stress which further exacerbates endothelial dysfunction (PMID: 20876676 ). This ultimately leads to atherosclerosis, peripheral artery disease and cardiovascular disease, which are common in patients with CKD (PMID: 33456671 ). In hemodialyzed patients, serum levels of indoxyl sulfate are associated with levels of pentosidine, a marker of carbonyl and oxidative stress (PMID: 14524578 ). In vitro, indoxyl sulfate increases reactive oxygen species (ROS) production in tubular cells and increases NAD(P)H oxidase activity in endothelial cells (PMID: 29976888 ). Indoxyl sulfate also strongly decreases the levels of glutathione, one of the most active antioxidant systems of the cell (PMID: 29474405 ). In addition to its well-known renal toxicity and cardiotoxicity, indoxyl sulfate appears to have osteotoxic, myotoxic and neurotoxic effects. As an osteotoxin, indoxyl sulfate impairs osteoblast function and induces abnormalities of bone turnover (PMID: 28781957 ). Indoxyl sulfate appears to induce low-turnover bone disease by directly acting on both osteoblasts and osteoclast precursors to suppress bone formation and bone resorption. In vitro studies with mouse osteoblasts have shown that indoxyl sulfate suppresses the gene expression of osterix, osteocalcin, and bone morphogenetic protein 2 (BMP2), thereby inhibiting the formation of mineralized bone nodules, leading to suppressed bone formation (PMID: 28781957 ). As a myotoxin, indoxyl sulfate appears to induce sarcopenia, which is especially common in patients with CKD. In particular, indoxyl sulfate increases the production of several factors related to skeletal muscle breakdown, including reactive oxygen species (ROS) and inflammatory cytokines (TNF-α, IL-6 and TGF-β1) (PMID: 27549031 ). It also enhances the production of muscle atrophy-related genes, myostatin and atrogin-1 (PMID: 27549031 ). As a neurotoxin, indoxyl sulfate appears to disrupt the blood brain barrier. In particular, indoxyl sulfate binds to the aryl hydrocarbon receptor (AhR), which is widely expressed in the central nervous system. The binding of indoxyl sulfate to the AhR leads to blood-brain barrier disruption, which is associated with cognitive impairment in animal models of CKD (PMID: 32527975 ). Indoxyl sulfate, along with quinolinic acid and kynurenine, are significantly elevated in blood/plasma of individuals with dementia (PMID: 34493657 ). Recently, indoxyl sulfate has been shown to be associated with altered neural processing (as shown by functional MRI) and the serum abundance of indoxyl sulfate is positively correlated with severity of psychic anxiety in humans (PMID: 34697401 ). |
---|
Structure | OS(=O)(=O)OC1=CNC2=CC=CC=C12 InChI=1S/C8H7NO4S/c10-14(11,12)13-8-5-9-7-4-2-1-3-6(7)8/h1-5,9H,(H,10,11,12) |
---|
Synonyms | Value | Source |
---|
3-Indolyl hydrogen sulfate | ChEBI | 3-Indolyl sulfate | ChEBI | 3-Indoxyl sulfate | ChEBI | 3-Indoxylsulfuric acid | ChEBI | Indican | ChEBI | indol-3-yl Hydrogen sulfate | ChEBI | indol-3-yl Sulfate | ChEBI | indol-3-yl Sulphate | ChEBI | Indoxyl sulfic acid | ChEBI | Indoxyl sulphate | ChEBI | Indoxyl-3-sulphate | ChEBI | Indoxylsulfuric acid | ChEBI | 3-Indolyl hydrogen sulfuric acid | Generator | 3-Indolyl hydrogen sulphate | Generator | 3-Indolyl hydrogen sulphuric acid | Generator | 3-Indolyl sulfuric acid | Generator | 3-Indolyl sulphate | Generator | 3-Indolyl sulphuric acid | Generator | 3-Indoxyl sulfuric acid | Generator | 3-Indoxyl sulphate | Generator | 3-Indoxyl sulphuric acid | Generator | 3-Indoxylsulfate | Generator | 3-Indoxylsulphate | Generator | 3-Indoxylsulphuric acid | Generator | indol-3-yl Hydrogen sulfuric acid | Generator | indol-3-yl Hydrogen sulphate | Generator | indol-3-yl Hydrogen sulphuric acid | Generator | indol-3-yl Sulfuric acid | Generator | indol-3-yl Sulphuric acid | Generator | Indoxyl sulfuric acid | Generator | Indoxyl sulphuric acid | Generator | Indoxyl-3-sulfate | Generator | Indoxyl-3-sulfuric acid | Generator | Indoxyl-3-sulphuric acid | Generator | Indoxylsulfate | Generator | Indoxylsulphate | Generator | Indoxylsulphuric acid | Generator | 1H-indol-3-yl Hydrogen sulfate | HMDB | 1H-indol-3-yl Hydrogen sulphate | HMDB | indol-3-Ol | HMDB | Indican monosodium salt | HMDB | Monopotassium salt, indican | HMDB | Monosodium salt, indican | HMDB | Sulfate, indoxyl | HMDB | Indican monopotassium salt | HMDB | 1H-indol-3-Ol hydrogen sulfate ester | HMDB | 3-Sulphooxy-1H-indole | HMDB | Indoxyl sulfate | Generator |
|
---|
Chemical Formula | C8H7NO4S |
---|
Average Molecular Weight | 213.21 |
---|
Monoisotopic Molecular Weight | 213.009578407 |
---|
IUPAC Name | (1H-indol-3-yl)oxidanesulfonic acid |
---|
Traditional Name | 3-sulfooxy-1H-indole |
---|
CAS Registry Number | 487-94-5 |
---|
SMILES | OS(=O)(=O)OC1=CNC2=CC=CC=C12 |
---|
InChI Identifier | InChI=1S/C8H7NO4S/c10-14(11,12)13-8-5-9-7-4-2-1-3-6(7)8/h1-5,9H,(H,10,11,12) |
---|
InChI Key | BXFFHSIDQOFMLE-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as arylsulfates. These are organic compounds containing a sulfate group that carries an aryl group through an ether group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Organic sulfuric acids and derivatives |
---|
Sub Class | Arylsulfates |
---|
Direct Parent | Arylsulfates |
---|
Alternative Parents | |
---|
Substituents | - Arylsulfate
- Indole
- Indole or derivatives
- Substituted pyrrole
- Sulfuric acid monoester
- Sulfate-ester
- Sulfuric acid ester
- Benzenoid
- Pyrrole
- Heteroaromatic compound
- Organoheterocyclic compound
- Azacycle
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organic oxide
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Indoxyl sulfate,1TMS,isomer #1 | C[Si](C)(C)OS(=O)(=O)OC1=C[NH]C2=CC=CC=C12 | 1999.5 | Semi standard non polar | 33892256 | Indoxyl sulfate,1TMS,isomer #1 | C[Si](C)(C)OS(=O)(=O)OC1=C[NH]C2=CC=CC=C12 | 1946.5 | Standard non polar | 33892256 | Indoxyl sulfate,1TMS,isomer #1 | C[Si](C)(C)OS(=O)(=O)OC1=C[NH]C2=CC=CC=C12 | 2919.9 | Standard polar | 33892256 | Indoxyl sulfate,1TMS,isomer #2 | C[Si](C)(C)N1C=C(OS(=O)(=O)O)C2=CC=CC=C21 | 2048.1 | Semi standard non polar | 33892256 | Indoxyl sulfate,1TMS,isomer #2 | C[Si](C)(C)N1C=C(OS(=O)(=O)O)C2=CC=CC=C21 | 2068.3 | Standard non polar | 33892256 | Indoxyl sulfate,1TMS,isomer #2 | C[Si](C)(C)N1C=C(OS(=O)(=O)O)C2=CC=CC=C21 | 2960.1 | Standard polar | 33892256 | Indoxyl sulfate,2TMS,isomer #1 | C[Si](C)(C)OS(=O)(=O)OC1=CN([Si](C)(C)C)C2=CC=CC=C12 | 2096.6 | Semi standard non polar | 33892256 | Indoxyl sulfate,2TMS,isomer #1 | C[Si](C)(C)OS(=O)(=O)OC1=CN([Si](C)(C)C)C2=CC=CC=C12 | 2130.4 | Standard non polar | 33892256 | Indoxyl sulfate,2TMS,isomer #1 | C[Si](C)(C)OS(=O)(=O)OC1=CN([Si](C)(C)C)C2=CC=CC=C12 | 2653.9 | Standard polar | 33892256 | Indoxyl sulfate,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OS(=O)(=O)OC1=C[NH]C2=CC=CC=C12 | 2283.9 | Semi standard non polar | 33892256 | Indoxyl sulfate,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OS(=O)(=O)OC1=C[NH]C2=CC=CC=C12 | 2199.5 | Standard non polar | 33892256 | Indoxyl sulfate,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OS(=O)(=O)OC1=C[NH]C2=CC=CC=C12 | 2945.2 | Standard polar | 33892256 | Indoxyl sulfate,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C=C(OS(=O)(=O)O)C2=CC=CC=C21 | 2320.7 | Semi standard non polar | 33892256 | Indoxyl sulfate,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C=C(OS(=O)(=O)O)C2=CC=CC=C21 | 2274.7 | Standard non polar | 33892256 | Indoxyl sulfate,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C=C(OS(=O)(=O)O)C2=CC=CC=C21 | 3011.9 | Standard polar | 33892256 | Indoxyl sulfate,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OS(=O)(=O)OC1=CN([Si](C)(C)C(C)(C)C)C2=CC=CC=C12 | 2519.6 | Semi standard non polar | 33892256 | Indoxyl sulfate,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OS(=O)(=O)OC1=CN([Si](C)(C)C(C)(C)C)C2=CC=CC=C12 | 2609.3 | Standard non polar | 33892256 | Indoxyl sulfate,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OS(=O)(=O)OC1=CN([Si](C)(C)C(C)(C)C)C2=CC=CC=C12 | 2763.0 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Indoxyl sulfate GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (Non-derivatized) | splash10-0fk9-1890000000-1ccefb12c0ecb58cd51f | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Indoxyl sulfate GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (Non-derivatized) | splash10-0bu0-1940000000-990f3edaa0f09b455534 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Indoxyl sulfate GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (Non-derivatized) | splash10-004i-0790000000-bc45c54af242dc72b9db | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Indoxyl sulfate GC-MS (Non-derivatized) - 70eV, Positive | splash10-01q9-1920000000-61513ebc6b785c807016 | 2017-08-28 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Indoxyl sulfate GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate Quattro_QQQ 10V, Negative-QTOF (Annotated) | splash10-03di-2090000000-53c9050daddd26dc4b7f | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate Quattro_QQQ 25V, Negative-QTOF (Annotated) | splash10-001i-9200000000-2fa7a5fde4214df01ed2 | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate Quattro_QQQ 40V, Negative-QTOF (Annotated) | splash10-001i-9000000000-c9eec4c054ae464098ed | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negative-QTOF | splash10-03di-0090000000-3cb045bd6bc8f7f8c2b0 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negative-QTOF | splash10-03e9-6290000000-83be1b2526f53131a6eb | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negative-QTOF | splash10-001i-9400000000-13c9487183bfd123ac3b | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negative-QTOF | splash10-001i-9100000000-cf4b2fd59d8e983cb538 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negative-QTOF | splash10-001i-9000000000-d0f51465d6c4ede36ea4 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Negative-QTOF | splash10-01si-9350000000-7227b62421572ea4e5f7 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate LC-ESI-QQ , negative-QTOF | splash10-03di-0090000000-8fc92d1f6e32863121d3 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate LC-ESI-QQ , negative-QTOF | splash10-03e9-6290000000-b9b7292552ce2dcfccff | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate LC-ESI-QQ , negative-QTOF | splash10-001i-9400000000-7348f8347e517b6e1de2 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate LC-ESI-QQ , negative-QTOF | splash10-001i-9100000000-e9a190cf92fcef264150 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate LC-ESI-QQ , negative-QTOF | splash10-001i-9000000000-d0f51465d6c4ede36ea4 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate LC-ESI-QTOF , negative-QTOF | splash10-01si-9350000000-7227b62421572ea4e5f7 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate , positive-QTOF | splash10-001i-0900000000-d5c9e813f433f6a44f0f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate 40V, Negative-QTOF | splash10-004i-9000000000-2ada8a129d47cf18cf2f | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate 10V, Negative-QTOF | splash10-03e9-8190000000-b7fa2468dad04ce9cf7b | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Indoxyl sulfate 20V, Negative-QTOF | splash10-0059-9300000000-4ef26d7f6ffd8a0309a8 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Indoxyl sulfate 10V, Positive-QTOF | splash10-03di-0290000000-bcbb5c8a331119233939 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Indoxyl sulfate 20V, Positive-QTOF | splash10-0159-0910000000-0d28f0b8a4ef10141bf2 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Indoxyl sulfate 40V, Positive-QTOF | splash10-014i-2900000000-a394015845114b618d01 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Indoxyl sulfate 10V, Negative-QTOF | splash10-03di-0190000000-6917b03dbdcafea36737 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Indoxyl sulfate 20V, Negative-QTOF | splash10-001i-0930000000-6cb7fcdb7b15b9a9e80a | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Indoxyl sulfate 40V, Negative-QTOF | splash10-001i-4900000000-3b57e4454fb97f3e1a1a | 2017-07-26 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, experimental) | 2012-12-04 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | 2012-12-05 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Cytoplasm
- Extracellular space
|
---|
Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
- Feces
- Urine
|
---|
Tissue Locations | - Bone Marrow
- Brain
- Endothelial tissue
- Heart
- Kidney
- Liver
- Skeletal Muscle
|
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 3.80 +/- 3.0017 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 14.0 +/- 4.2 uM | Adult (>18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 2.49 +/- 1.36 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.040 +/- 0.038 uM | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 129.0 (45.0-191.0) umol/mmol creatinine | Children (1-13 years old) | Both | Normal | | details | Urine | Detected and Quantified | 19.74 +/- 5.26 umol/mmol creatinine | Adult (>18 years old) | Male | Normal | | details | Urine | Detected and Quantified | 17.76 +/- 6.58 umol/mmol creatinine | Adult (>18 years old) | Female | Normal | | details | Urine | Detected and Quantified | 1.41-51.64 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 41.689 +/- 44.971 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Normal | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 18.98 umol/mmol creatinine | Adult (>18 years old) | Male | Normal | | details | Urine | Detected and Quantified | >0.658 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 22.4 (6.0-64.8) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 2.57 (1.67-4.03) umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | Urine | Detected and Quantified | 420 +/- 210 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 3.80 +/- 2.44 uM | Adult (>18 years old) | Both | Parkinson’s disease | | details | Blood | Detected and Quantified | 21.11 +/- 12.20 uM | Adult (>18 years old) | Both | uremia | | details | Blood | Detected and Quantified | 3.80 +/- 2.20 uM | Adult (>18 years old) | Both | Parkinson’s disease with motor fluctuation | | details | Blood | Detected and Quantified | 3.80 +/- 2.67 uM | Adult (>18 years old) | Both | Parkinson’s disease without motor fluctuation | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.043 +/- 0.013 uM | Adult (>18 years old) | Both | Parkinson’s disease | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.051 +/- 0.028 uM | Adult (>18 years old) | Both | Parkinson’s disease with motor fluctuation | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.035 +/- 0.0070 uM | Adult (>18 years old) | Both | Parkinson’s disease without motor fluctuation | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | Urine | Detected and Quantified | 36.932 +/- 21.826 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Eosinophilic esophagitis | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Uremia |
---|
- Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul;23(7):1258-70. doi: 10.1681/ASN.2011121175. Epub 2012 May 24. [PubMed:22626821 ]
| Colorectal cancer |
---|
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
| Eosinophilic esophagitis |
---|
- Slae, M., Huynh, H., Wishart, D.S. (2014). Analysis of 30 normal pediatric urine samples via NMR spectroscopy (unpublished work). NA.
|
|
---|
Associated OMIM IDs | - 114500 (Colorectal cancer)
- 610247 (Eosinophilic esophagitis)
|
---|
External Links |
---|
DrugBank ID | DB07992 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB022179 |
---|
KNApSAcK ID | C00052323 |
---|
Chemspider ID | 9840 |
---|
KEGG Compound ID | Not Available |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Indoxyl sulfate |
---|
METLIN ID | 524 |
---|
PubChem Compound | 10258 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 43355 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | MDB00000217 |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Robertson, Alexander. Synthesis of glucosides. I. Synthesis of indican. Journal of the Chemical Society (1927), 1937-43. |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Sweatman BC, Farrant RD, Holmes E, Ghauri FY, Nicholson JK, Lindon JC: 600 MHz 1H-NMR spectroscopy of human cerebrospinal fluid: effects of sample manipulation and assignment of resonances. J Pharm Biomed Anal. 1993 Aug;11(8):651-64. [PubMed:8257730 ]
- Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. [PubMed:19212411 ]
- Bales JR, Higham DP, Howe I, Nicholson JK, Sadler PJ: Use of high-resolution proton nuclear magnetic resonance spectroscopy for rapid multi-component analysis of urine. Clin Chem. 1984 Mar;30(3):426-32. [PubMed:6321058 ]
- Aoyama I, Miyazaki T, Niwa T: Preventive effects of an oral sorbent on nephropathy in rats. Miner Electrolyte Metab. 1999 Jul-Dec;25(4-6):365-72. [PubMed:10681668 ]
- Brunet P, Dou L, Cerini C, Berland Y: Protein-bound uremic retention solutes. Adv Ren Replace Ther. 2003 Oct;10(4):310-20. [PubMed:14681860 ]
- Niwa T, Ise M: Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med. 1994 Jul;124(1):96-104. [PubMed:8035108 ]
- Iwasaki Y: [Uremic toxins and bone metabolism]. Clin Calcium. 2007 May;17(5):734-9. [PubMed:17471003 ]
- Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P: The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost. 2007 Jun;5(6):1302-8. [PubMed:17403109 ]
- Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul;23(7):1258-70. doi: 10.1681/ASN.2011121175. Epub 2012 May 24. [PubMed:22626821 ]
- Zhang LS, Davies SS: Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med. 2016 Apr 21;8(1):46. doi: 10.1186/s13073-016-0296-x. [PubMed:27102537 ]
- Evenepoel P, Meijers BK, Bammens BR, Verbeke K: Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl. 2009 Dec;(114):S12-9. doi: 10.1038/ki.2009.402. [PubMed:19946322 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
- Edamatsu T, Fujieda A, Itoh Y: Phenyl sulfate, indoxyl sulfate and p-cresyl sulfate decrease glutathione level to render cells vulnerable to oxidative stress in renal tubular cells. PLoS One. 2018 Feb 23;13(2):e0193342. doi: 10.1371/journal.pone.0193342. eCollection 2018. [PubMed:29474405 ]
- Banoglu E, Jha GG, King RS: Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate. Eur J Drug Metab Pharmacokinet. 2001 Oct-Dec;26(4):235-40. doi: 10.1007/BF03226377. [PubMed:11808865 ]
- Banoglu E, King RS: Sulfation of indoxyl by human and rat aryl (phenol) sulfotransferases to form indoxyl sulfate. Eur J Drug Metab Pharmacokinet. 2002 Apr-Jun;27(2):135-40. doi: 10.1007/BF03190428. [PubMed:12064372 ]
- King J, Mihaila SM, Ahmed S, Truckenmuller R, Giselbrecht S, Masereeuw R, Carlier A: The Influence of OAT1 Density and Functionality on Indoxyl Sulfate Transport in the Human Proximal Tubule: An Integrated Computational and In Vitro Study. Toxins (Basel). 2021 Sep 22;13(10). pii: toxins13100674. doi: 10.3390/toxins13100674. [PubMed:34678967 ]
- Bobot M, Thomas L, Moyon A, Fernandez S, McKay N, Balasse L, Garrigue P, Brige P, Chopinet S, Poitevin S, Cerini C, Brunet P, Dignat-George F, Burtey S, Guillet B, Hache G: Uremic Toxic Blood-Brain Barrier Disruption Mediated by AhR Activation Leads to Cognitive Impairment during Experimental Renal Dysfunction. J Am Soc Nephrol. 2020 Jul;31(7):1509-1521. doi: 10.1681/ASN.2019070728. Epub 2020 Jun 11. [PubMed:32527975 ]
- Gao H, Liu S: Role of uremic toxin indoxyl sulfate in the progression of cardiovascular disease. Life Sci. 2017 Sep 15;185:23-29. doi: 10.1016/j.lfs.2017.07.027. Epub 2017 Jul 25. [PubMed:28754616 ]
- Cheng TH, Ma MC, Liao MT, Zheng CM, Lu KC, Liao CH, Hou YC, Liu WC, Lu CL: Indoxyl Sulfate, a Tubular Toxin, Contributes to the Development of Chronic Kidney Disease. Toxins (Basel). 2020 Oct 29;12(11). pii: toxins12110684. doi: 10.3390/toxins12110684. [PubMed:33138205 ]
- Lekawanvijit S: Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome. Toxins (Basel). 2018 Sep 1;10(9). pii: toxins10090352. doi: 10.3390/toxins10090352. [PubMed:30200452 ]
- Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P: The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int. 2004 Feb;65(2):442-51. doi: 10.1111/j.1523-1755.2004.00399.x. [PubMed:14717914 ]
- Yu M, Kim YJ, Kang DH: Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol. 2011 Jan;6(1):30-9. doi: 10.2215/CJN.05340610. Epub 2010 Sep 28. [PubMed:20876676 ]
- Kwiatkowska I, Hermanowicz JM, Mysliwiec M, Pawlak D: Oxidative Storm Induced by Tryptophan Metabolites: Missing Link between Atherosclerosis and Chronic Kidney Disease. Oxid Med Cell Longev. 2020 Dec 29;2020:6656033. doi: 10.1155/2020/6656033. eCollection 2020. [PubMed:33456671 ]
- Kato A, Odamaki M, Hishida A: Association between blood indoxyl sulfate and carbonyl stress marker in hemodialysis patients. Clin Nephrol. 2003 Sep;60(3):161-7. doi: 10.5414/cnp60161. [PubMed:14524578 ]
- Dias GF, Bonan NB, Steiner TM, Tozoni SS, Rodrigues S, Nakao LS, Kuntsevich V, Pecoits Filho R, Kotanko P, Moreno-Amaral AN: Indoxyl Sulfate, a Uremic Toxin, Stimulates Reactive Oxygen Species Production and Erythrocyte Cell Death Supposedly by an Organic Anion Transporter 2 (OAT2) and NADPH Oxidase Activity-Dependent Pathways. Toxins (Basel). 2018 Jul 5;10(7). pii: toxins10070280. doi: 10.3390/toxins10070280. [PubMed:29976888 ]
- Watanabe K, Tominari T, Hirata M, Matsumoto C, Hirata J, Murphy G, Nagase H, Miyaura C, Inada M: Indoxyl sulfate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption. FEBS Open Bio. 2017 Jul 20;7(8):1178-1185. doi: 10.1002/2211-5463.12258. eCollection 2017 Aug. [PubMed:28781957 ]
- Enoki Y, Watanabe H, Arake R, Sugimoto R, Imafuku T, Tominaga Y, Ishima Y, Kotani S, Nakajima M, Tanaka M, Matsushita K, Fukagawa M, Otagiri M, Maruyama T: Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. Sci Rep. 2016 Aug 23;6:32084. doi: 10.1038/srep32084. [PubMed:27549031 ]
- Teruya T, Chen YJ, Kondoh H, Fukuji Y, Yanagida M: Whole-blood metabolomics of dementia patients reveal classes of disease-linked metabolites. Proc Natl Acad Sci U S A. 2021 Sep 14;118(37). pii: 2022857118. doi: 10.1073/pnas.2022857118. [PubMed:34493657 ]
- Brydges CR, Fiehn O, Mayberg HS, Schreiber H, Dehkordi SM, Bhattacharyya S, Cha J, Choi KS, Craighead WE, Krishnan RR, Rush AJ, Dunlop BW, Kaddurah-Daouk R: Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature. Sci Rep. 2021 Oct 25;11(1):21011. doi: 10.1038/s41598-021-99845-1. [PubMed:34697401 ]
|
---|